Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies.
Standard
Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies. / Ayuketang Ayuk, Francis; Maywald, Nadja; Hannemann, Sandra; Larsen, Ulrike; Zander, Axel R.; Kröger, Nicolaus.
In: ANTICANCER RES, Vol. 29, No. 4, 4, 2009, p. 1355-1360.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies.
AU - Ayuketang Ayuk, Francis
AU - Maywald, Nadja
AU - Hannemann, Sandra
AU - Larsen, Ulrike
AU - Zander, Axel R.
AU - Kröger, Nicolaus
PY - 2009
Y1 - 2009
N2 - OBJECTIVE: The cytotoxic effects of 4 ATG preparations (Thymoglobulin, ATG-Fresenius, Lymphoglobulin and ATGAM) in hematological malignancies were compared. MATERIALS AND METHODS: Myeloma, myeloid leukaemia and lymphoma cell lines as well as primary CLL and T-cell samples were used. Cells were incubated at 1x10 (6)/mL with 50-500 microg/mL of various ATG preparations with or without complement. Cell viability was analyzed by flow cytometry. RESULTS: All ATG preparations had potent and similar cytotoxic activity against T-cells, primary CLL cells, NHL cell lines and myeloma cell lines. Resistance of U266 myeloma cells to ATG-induced apoptosis is shared by all 4 ATGs and can be overcome by addition of complement. CONCLUSION: All 4 ATGs have similar cytotoxic activity against hematological malignancies in vitro. If ATGs are used to target hematological malignancies, the choice of which ATG to use would depend on whether the required ATG concentration can be achieved in vivo.
AB - OBJECTIVE: The cytotoxic effects of 4 ATG preparations (Thymoglobulin, ATG-Fresenius, Lymphoglobulin and ATGAM) in hematological malignancies were compared. MATERIALS AND METHODS: Myeloma, myeloid leukaemia and lymphoma cell lines as well as primary CLL and T-cell samples were used. Cells were incubated at 1x10 (6)/mL with 50-500 microg/mL of various ATG preparations with or without complement. Cell viability was analyzed by flow cytometry. RESULTS: All ATG preparations had potent and similar cytotoxic activity against T-cells, primary CLL cells, NHL cell lines and myeloma cell lines. Resistance of U266 myeloma cells to ATG-induced apoptosis is shared by all 4 ATGs and can be overcome by addition of complement. CONCLUSION: All 4 ATGs have similar cytotoxic activity against hematological malignancies in vitro. If ATGs are used to target hematological malignancies, the choice of which ATG to use would depend on whether the required ATG concentration can be achieved in vivo.
M3 - SCORING: Zeitschriftenaufsatz
VL - 29
SP - 1355
EP - 1360
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 4
M1 - 4
ER -
